CoChat
Sign Up
Cited by 19

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Birch Pollen Allergens

Guan, Kai, Li, Lisha, Chang, Christopher·2022·Current Protein & Peptide Science
DOI 10.2174/1389203723666220815095725
Open this paper in CoChat — free account

Abstract

Birch belongs to order Fagales and family Betulaceae. Birch pollen is one of the most important airborne inhaled allergens in the north temperate zone, leading to allergic rhinitis, asthma and pollen-related food allergy. The sensitization rate to birch pollen is about 8-16% in the general populations and 7-57% in patients seen at various allergy centers. Seven birch pollen allergens have been recognized by the International Allergen Nomenclature Sub-committee, with Bet v 1 as the sole major allergen. Component-resolved diagnostics can help to discriminate broad cross-reactivity and false-positive diagnoses of pollen allergy caused by specific IgE to pan-allergens such as Bet v 2, 4 or Bet v 7 from true birch allergy represented by the major allergen Bet v 1-specific IgE. Patients with allergic symptoms to birch pollen showed significantly higher serum anti-Bet v 1 IgE concentrations than asymptomatic individuals with birch sensitization. Higher level of IgE to Bet v 1 also predicted oral allergy syndrome after the ingestion of Rosaceae fruits, nuts, or Apiaceae vegetables, which have cross-reactive homologous allergens with birch allergens. Bet v 1 is one of the first allergens developed using recombinant technology. Many forms of genetically modified Bet v 1 hypo-allergens have been developed and have shown benefit in animal models or even clinical trials of allergen immunotherapy.

Overview

Integrity signals

Registry

Crossref · 10.2174/1389203723666220815095725

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 2 references

Research works printed but not linked: 104

  1. Asam C.; Hofer H.; Wolf M.; Aglas L.; Wallner M.; Tree pollen allergens-an update from a molecular perspective. Allergy 2015,70(10),1201-1211 · DOI
  2. Kishikawa R.; Kotoh E.; Oshikawa C.; Soh N.; Shimoda T.; Saito A.; Sahashi N.; Enomoto T.; Usami A.; Teranishi H.; Fujisaki Y.; Yokoyama T.; Murayama K.; Imai T.; Fukutomi Y.; Taniguchi M.; Iwanaga T.; Longitudinal monitoring of tree airborne pollen in Japan. Arerugi 2017,66(2),97-111
  3. Xie Z.; Yin J.; Chinese birch pollen allergy and immunotherapy in mice. Inflammation 2019,42(3),961-972 · DOI
  4. Shin J.Y.; Han M.J.; Cho C.; Kim K.R.; Ha J.C.; Oh J.W.; Allergenic pollen calendar in korea based on probability distribution models and up-to-date observations. Allergy Asthma Immunol Res 2020,12(2),259-273 · DOI
  5. Lo F.; Bitz C.M.; Battisti D.S.; Hess J.J.; Pollen calendars and maps of allergenic pollen in North America. Aerobiologia 2019,35(4),613-633 · DOI
  6. Biedermann T.; Winther L.; Till S.J.; Panzner P.; Knulst A.; Valovirta E.; Birch pollen allergy in Europe. Allergy 2019,74(7),1237-1248 · DOI · Paper page
  7. Lind T.; Ekebom A.; Alm Kübler K.; Östensson P.; Bellander T.; Lõhmus M.; Pollen season trends (1973-2013) in Stockholm area, Sweden. PLoS One 2016,11(11),e0166887 · DOI
  8. Niederberger V.; Pauli G.; Grönlund H.; Fröschl R.; Rumpold H.; Kraft D.; Valenta R.; Spitzauer S.; Recombinant birch pollen aller-gens (rBet v 1 and rBet v 2) contain most of the IgE epitopes present in birch, alder, hornbeam, hazel, and oak pollen: A quantitative IgE inhibition study with sera from different populations. J Allergy Clin Immunol 1998,102(4),579-591 · DOI
  9. D’Amato G.; Spieksma F.T.; Liccardi G.; Jäger S.; Russo M.; Kontou-Fili K.; Nikkels H.; Wüthrich B.; Bonini S.; Pollen-related allergy in Europe. Allergy 1998,53(6),567-578 · DOI
  10. Wüthrich B.; Schindler C.; Leuenberger P.; Ackermann-Liebrich U.; Prevalence of atopy and pollinosis in the adult population of Switzerland (SAPALDIA study). Int Arch Allergy Immunol 1995,106(2),149-156 · DOI · Paper page
  11. Linneberg A.; Nielsen N.H.; Madsen F.; Frølund L.; Dirksen A.; Jørgensen T.; Increasing prevalence of specific IgE to aeroallergens in an adult population: Two cross-sectional surveys 8 years apart: The Copenhagen allergy study. J Allergy Clin Immunol 2000,106(2),247-252 · DOI
  12. Schmitz R.; Ellert U.; Kalcklösch M.; Dahm S.; Thamm M.; Patterns of sensitization to inhalant and food allergens - findings from the German health interview and examination survey for children and adolescents. Int Arch Allergy Immunol 2013,162(3),263-270 · DOI
  13. Saijo Y.; Yoshioka E.; Sato Y.; Miyamoto T.; Sengoku K.; Ito Y.; Itoh S.; Miyashita C.; Araki A.; Kishi R.; Japan E.; Factors correlating with serum birch pollen IgE status in pregnant women in Hokkaido, Japan: The Japan Environment and Children’s Study (JECS). World Allergy Organ J 2020,13(6),100128 · DOI
  14. Bruffaerts N.; De Smedt T.; Delcloo A.; Simons K.; Hoebeke L.; Verstraeten C.; Van Nieuwenhuyse A.; Packeu A.; Hendrickx M.; Comparative long-term trend analysis of daily weather conditions with daily pollen concentrations in Brussels, Belgium. Int J Biometeorol 2018,62(3),483-491 · DOI
  15. Frei T.; Gassner E.; Climate change and its impact on birch pollen quantities and the start of the pollen season an example from Switzerland for the period 1969-2006. Int J Biometeorol 2008,52(7),667-674 · DOI
  16. Troise C.; Voltolini S.; Delbono G.; Negrini A.C.; Allergy to pollens from Betulaceae and Corylaceae in a Mediterranean area (Genoa, Italy)--a ten-year retrospective study. J Investig Allergol Clin Immunol 1992,2(6),313-317
  17. Warm K.; Lindberg A.; Lundbäck B.; Rönmark E.; Increase in sensitization to common airborne allergens among adults - two population-based studies 15 years apart. Allergy Asthma Clin Immunol 2013,9(1),20 · DOI
  18. Burbach G.J.; Heinzerling L.M.; Edenharter G.; Bachert C.; Bindslev-Jensen C.; Bonini S.; Bousquet J.; Bousquet-Rouanet L.; Bousquet P.J.; Bresciani M.; Bruno A.; Canonica G.W.; Darsow U.; Demoly P.; Durham S.; Fokkens W.J.; Giavi S.; Gjomarkaj M.; Gramiccioni C.; Haahtela T.; Kowalski M.L.; Magyar P.; Muraközi G.; Orosz M.; Papadopoulos N.G.; Röhnelt C.; Stingl G.; Todo-Bom A.; Von Mutius E.; Wiesner A.; Wöhrl S.; Zuberbier T.; GA(2)LEN skin test study II: Clinical relevance of inhalant allergen sensitizations in Europe. Allergy 2009,64(10),1507-1515 · DOI
  19. Kim J.H.; Kim S.H.; Park H.W.; Cho S.H.; Chang Y.S.; Oral Allergy Syndrome in Birch Pollen-Sensitized Patients from a Korean University Hospital. J Korean Med Sci 2018,33(33),e218 · DOI
  20. Li J.D.; Du Z.R.; Liu J.; Xu Y.Y.; Wang R.Q.; Yin J.; Characteristics of pollen-related food allergy based on individual pollen allergy profiles in the Chinese population. World Allergy Organ J 2020,13(5),100120 · DOI
  21. Ipsen H.; Løwenstein H.; Isolation and immunochemical characterization of the major allergen of birch pollen (Betula verrucosa). J Allergy Clin Immunol 1983,72(2),150-159 · DOI
  22. Breiteneder H.; Pettenburger K.; Bito A.; Valenta R.; Kraft D.; Rumpold H.; Scheiner O.; Breitenbach M.; The gene coding for the major birch pollen allergen Betv1, is highly homologous to a pea disease resistance response gene. EMBO J 1989,8(7),1935-1938 · DOI
  23. Hao G.D.; Zheng Y.W.; Wang Z.X.; Kong X.A.; Song Z.J.; Lai X.X.; Spangfort M.D.; High correlation of specific IgE sensitization between birch pollen, soy and apple allergens indicates pollen-food allergy syndrome among birch pollen allergic patients in northern China. J Zhejiang Univ Sci B 2016,17(5),399-404 · DOI
  24. Ciprandi G.; Comite P.; Mussap M.; De Amici M.; Quaglini S.; Barocci F.; Marseglia G.L.; Scala E.; Profiles of birch sensitization (Bet v 1, Bet v 2, and Bet v 4) and oral allergy syndrome across Italy. J Investig Allergol Clin Immunol 2016,26(4),244-248 · DOI
  25. Swoboda I.; Jilek A.; Ferreira F.; Engel E.; Hoffmann-Sommergruber K.; Scheiner O.; Kraft D.; Breiteneder H.; Pittenauer E.; Schmid E.; Isoforms of Bet v 1, the major birch pollen allergen, analyzed by liquid chromatography, mass spectrometry, and cDNA cloning. J Biol Chem 1995,270(6),2607-2613 · DOI
  26. Fernandes H.; Michalska K.; Sikorski M.; Jaskolski M.; Structural and functional aspects of PR-10 proteins. FEBS J 2013,280(5),1169-1199 · DOI
  27. Mogensen J.E.; Wimmer R.; Larsen J.N.; Spangfort M.D.; Otzen D.E.; The major birch allergen, Bet v 1, shows affinity for a broad spectrum of physiological ligands. J Biol Chem 2002,277(26),23684-23692 · DOI
  28. Aglas L.; Soh W.T.; Kraiem A.; Wenger M.; Brandstetter H.; Ferreira F.; Ligand binding of PR-10 proteins with a particular focus on the Bet v 1 allergen family. Curr Allergy Asthma Rep 2020,20(7),25 · DOI · Paper page
  29. Soh W.T.; Aglas L.; Mueller G.A.; Gilles S.; Weiss R.; Scheiblhofer S.; Huber S.; Scheidt T.; Thompson P.M.; Briza P.; London R.E.; Traidl-Hoffmann C.; Cabrele C.; Brandstetter H.; Ferreira F.; Multiple roles of Bet v 1 ligands in allergen stabilization and modulation of endosomal protease activity. Allergy 2019,74(12),2382-2393 · DOI
  30. Gepp B.; Lengger N.; Bublin M.; Hemmer W.; Breiteneder H.; Radauer C.; Chimeras of Bet v 1 and Api g 1 reveal heterogeneous IgE responses in patients with birch pollen allergy. J Allergy Clin Immunol 2014,134(1),188-194 · DOI
  31. Schmalz S.; Mayr V.; Shosherova A.; Gepp B.; Ackerbauer D.; Sturm G.; Bohle B.; Breiteneder H.; Radauer C.; Isotype-specific binding patterns of serum antibodies to multiple conformational epitopes of Bet v 1. J Allergy Clin Immunol 2022,149(5),1786-94 · DOI
  32. Smole U.; Balazs N.; Hoffmann-Sommergruber K.; Radauer C.; Hafner C.; Wallner M.; Ferreira F.; Grössinger R.; de Jong E.C.; Wagner S.; Breiteneder H.; Differential T-cell responses and allergen uptake after exposure of dendritic cells to the birch pollen allergens Bet v 1.0101, Bet v 1.0401 and Bet v 1.1001. Immunobiology 2010,215(11),903-909 · DOI
  33. Seutter von Loetzen C.; Jacob T.; Hartl-Spiegelhauer O.; Vogel L.; Schiller D.; Spörlein-Güttler C.; Schobert R.; Vieths S.; Hartl M.J.; Rösch P.; Ligand recognition of the major birch pollen allergen Bet v 1 is isoform dependent. PLoS One 2015,10(6),e0128677 · DOI
  34. Popescu F.D.; Cross-reactivity between aeroallergens and food allergens. World J Methodol 2015,5(2),31-50 · DOI · Paper page
  35. Santoni M.; Ciardiello M.A.; Zampieri R.; Pezzotti M.; Giangrieco I.; Rafaiani C.; Ciancamerla M.; Mari A.; Avesani L.; Plant-made bet v 1 for molecular diagnosis. Front Plant Sci 2019,10,1273 · DOI
  36. Yamada Y.; Kidoguchi M.; Yata A.; Nakamura T.; Yoshida H.; Kato Y.; Masuko H.; Hizawa N.; Fujieda S.; Noguchi E.; Miura K.; High-yield production of the major birch pollen allergen bet v 1 with allergen immunogenicity in Nicotiana benthamiana. Front Plant Sci 2020,11,344 · DOI
  37. Hirschl S.; Ralser C.; Asam C.; Gangitano A.; Huber S.; Ebner C.; Bohle B.; Wolf M.; Briza P.; Ferreira F.; Griesbeck C.; Wallner M.; Expression and Characterization of Functional Recombinant Bet v 1.0101 in the chloroplast of Chlamydomonas reinhardtii. Int Arch Allergy Immunol 2017,173(1),44-50 · DOI
  38. Rossi R.E.; Monasterolo G.; Monasterolo S.; Detection of specific IgE antibodies in the sera of patients allergic to birch pollen using recombinant allergens Bet v 1, Bet v 2, Bet v 4: Evaluation of different IgE reactivity profiles. Allergy 2003,58(9),929-932 · DOI
  39. Fedorov A.A.; Ball T.; Mahoney N.M.; Valenta R.; Almo S.C.; The molecular basis for allergen cross-reactivity: Crystal structure and IgE-epitope mapping of birch pollen profilin. Structure 1997,5(1),33-45 · DOI
  40. Offermann L.R.; Schlachter C.R.; Perdue M.L.; Majorek K.A.; He J.Z.; Booth W.T.; Garrett J.; Kowal K.; Chruszcz M.; Structural, functional, and immunological characterization of profilin panallergens amb a 8, Art v 4, and Bet v 2. J Biol Chem 2016,291(30),15447-15459 · DOI
  41. Valenta R.; Duchêne M.; Pettenburger K.; Sillaber C.; Valent P.; Bettelheim P.; Breitenbach M.; Rumpold H.; Kraft D.; Scheiner O.; Identification of profilin as a novel pollen allergen; IgE autoreactivity in sensitized individuals. Science 1991,253(5019),557-560 · DOI
  42. Cudowska B.; Kaczmarski M.; Diagnostic value of birch recombinant allergens (rBet v 1, profilin rBet v 2) in children with pollen-related food allergy. Rocz Akad Med Bialymst 2004,49,111-115
  43. Seiberler S.; Scheiner O.; Kraft D.; Lonsdale D.; Valenta R.; Characterization of a birch pollen allergen, Bet v III, representing a novel class of Ca2+ binding proteins: Specific expression in mature pollen and dependence of patients’ IgE binding on protein-bound Ca2+. EMBO J 1994,13(15),3481-3486 · DOI
  44. Tinghino R.; Twardosz A.; Barletta B.; Puggioni E.M.; Iacovacci P.; Butteroni C.; Afferni C.; Mari A.; Hayek B.; Di Felice G.; Focke M.; Westritschnig K.; Valenta R.; Pini C.; Molecular, structural, and immunologic relationships between different families of recombinant calcium-binding pollen allergens. J Allergy Clin Immunol 2002,109(2),314-320 · DOI
  45. Panzner P.; Vachová M.; Vítovcová P.; Brodská P.; Vlas T.; A comprehensive analysis of middle-European molecular sensitization profiles to pollen allergens. Int Arch Allergy Immunol 2014,164(1),74-82 · DOI
  46. Shirasaki H.; Yamamoto T.; Koyanagi Y.; Watanabe N.; Himi T.; Detection of specific IgE antibodies in sera of Japanese birch-allergic patients using recombinant allergens Bet v 1, Bet v 2 and Bet v 4. Allergol Int 2008,57(1),93-96 · DOI
  47. Twardosz A.; Hayek B.; Seiberler S.; Vangelista L.; Elfman L.; Grönlund H.; Kraft D.; Valenta R.; Molecular characterization, expres-sion in Escherichia coli, and epitope analysis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4. Biochem Biophys Res Commun 1997,239(1),197-204 · DOI
  48. Wellhausen A.; Schöning B.; Petersen A.; Vieths S.; IgE binding to a new cross-reactive structure: A 35 kDa protein in birch pollen, exotic fruit and other plant foods. Z Ernährungswiss 1996,35(4),348-355 · DOI
  49. Vieths S.; Scheurer S.; Ballmer-Weber B.; Current understanding of cross-reactivity of food allergens and pollen. Ann N Y Acad Sci 2002,964,47-68 · DOI
  50. Karamloo F.; Schmitz N.; Scheurer S.; Foetisch K.; Hoffmann A.; Haustein D.; Vieths S.; Molecular cloning and characterization of a birch pollen minor allergen, Bet v 5, belonging to a family of isoflavone reductase-related proteins. J Allergy Clin Immunol 1999,104(5),991-999 · DOI
  51. Cadot P.; Diaz J.F.; Proost P.; Van Damme J.; Engelborghs Y.; Stevens E.A.; Ceuppens J.L.; Purification and characterization of an 18-kd allergen of birch (Betula verrucosa) pollen: Identification as a cyclophilin. J Allergy Clin Immunol 2000,105(2 Pt 1),286-291 · DOI
  52. Cadot P.; Nelles L.; Srahna M.; Dilissen E.; Ceuppens J.L.; Cloning and expression of the cyclophilin Bet v 7, and analysis of immunological cross-reactivity among the cyclophilin A family. Mol Immunol 2006,43(3),226-235 · DOI
  53. Deifl S.; Zwicker C.; Vejvar E.; Kitzmüller C.; Gadermaier G.; Nagl B.; Vrtala S.; Briza P.; Zlabinger G.J.; Jahn-Schmid B.; Ferreira F.; Bohle B.; Glutathione-S-transferase: A minor allergen in birch pollen due to limited release from hydrated pollen. PLoS One 2014,9(9),e109075 · DOI
  54. Ciprandi G.; Comite P.; Ferrero F.; Bignardi D.; Minale P.; Voltolini S.; Troise C.; Mussap M.; Birch allergy and oral allergy syndrome: The practical relevance of serum immunoglobulin E to Bet v 1. Allergy Asthma Proc 2016,37(1),43-49 · DOI · Paper page
  55. Elisyutina O.; Fedenko E.; Campana R.; Litovkina A.; Ilina N.; Kudlay D.; Egorenkov E.; Smirnov V.; Valenta R.; Lupinek C.; Khai-tov M.; Bet v 1-specific IgE levels and PR-10 reactivity discriminate silent sensitization from phenotypes of birch allergy. Allergy 2019,74(12),2525-2528 · DOI
  56. Kleine-Tebbe J.; Ackermann-Simon J.; Hanf G.; Molecular allergy diagnosis using pollen marker allergens and pollen panallergens: Five patterns seen in multiple test reactions to pollen extracts. Allergol Select 2021,5,180-186 · DOI
  57. San Nicoló M.; Braun T.; Eder K.; Berghaus A.; Gröger M.; Clinical relevance of IGE to profilin and/or polcalcin in pollen-sensitized patients. Int Arch Allergy Immunol 2016,169(2),101-107 · DOI
  58. Wölbing F.; Kunz J.; Kempf W.E.; Grimmel C.; Fischer J.; Biedermann T.; The clinical relevance of birch pollen profilin cross-reactivity in sensitized patients. Allergy 2017,72(4),562-569 · DOI
  59. Gellrich D.; Eder K.; San Nicoló M.; Berghaus A.; Gröger M.; The clinical impact of Bet v 6 in birch pollen-sensitized patients. Int Arch Allergy Immunol 2017,173(1),34-43 · DOI · Paper page
  60. Gevaert P.; De Craemer J.; De Ruyck N.; Rottey S.; de Hoon J.; Hellings P.W.; Volckaert B.; Lesneuck K.; Orengo J.M.; Atanasio A.; Kamal M.A.; Abdallah H.; Kamat V.; Dingman R.; DeVeaux M.; Ramesh D.; Perlee L.; Wang C.Q.; Weinreich D.M.; Herman G.; Yancopoulos G.D.; O’Brien M.P.; Novel antibody cocktail targeting Bet v 1 rapidly and sustainably treats birch allergy symptoms in a phase 1 study. J Allergy Clin Immunol 2022,149(1),189-199 · DOI
  61. Klimek L.; Bachert C.; Lukat K.F.; Pfaar O.; Meyer H.; Narkus A.; Allergy immunotherapy with a hypoallergenic recombinant birch pollen allergen rBet v 1-FV in a randomized controlled trial. Clin Transl Allergy 2015,5,28 · DOI · Paper page
  62. Treudler R.; Franke A.; Schmiedeknecht A.; Ballmer-Weber B.; Worm M.; Werfel T.; Jappe U.; Biedermann T.; Schmitt J.; Brehler R.; Kleinheinz A.; Kleine-Tebbe J.; Brüning H.; Ruëff F.; Ring J.; Saloga J.; Schäkel K.; Holzhauser T.; Vieths S.; Simon J.C.; BA-SALIT trial: Double-blind placebo-controlled allergen immunotherapy with rBet v 1-FV in birch-related soya allergy. Allergy 2017,72(8),1243-1253 · DOI
  63. Meyer W.; Narkus A.; Salapatek A.M.; Häfner D.; Double-blind, placebo-controlled, dose-ranging study of new recombinant hypoaller-genic Bet v 1 in an environmental exposure chamber. Allergy 2013,68(6),724-731 · DOI · Paper page
  64. Spertini F.; Perrin Y.; Audran R.; Pellaton C.; Boudousquié C.; Barbier N.; Thierry A.C.; Charlon V.; Reymond C.; Safety and immunogenicity of immunotherapy with Bet v 1-derived contiguous overlapping peptides. J Allergy Clin Immunol 2014,134(1),239-240.e13 · DOI
  65. Spertini F.; DellaCorte G.; Kettner A.; de Blay F.; Jacobsen L.; Jutel M.; Worm M.; Charlon V.; Reymond C.; Efficacy of 2 months of allergen-specific immunotherapy with Bet v 1-derived contiguous overlapping peptides in patients with allergic rhinoconjunctivitis: Results of a phase IIb study. J Allergy Clin Immunol 2016,138(1),162-168 · DOI
  66. Nony E.; Bouley J.; Le Mignon M.; Lemoine P.; Jain K.; Horiot S.; Mascarell L.; Pallardy M.; Vincentelli R.; Leone P.; Roussel A.; Batard T.; Abiteboul K.; Robin B.; de Beaumont O.; Arvidsson M.; Rak S.; Moingeon P.; Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients. Allergy 2015,70(7),795-804 · DOI
  67. Kinaciyan T.; Nagl B.; Faustmann S.; Frommlet F.; Kopp S.; Wolkersdorfer M.; Wöhrl S.; Bastl K.; Huber H.; Berger U.; Bohle B.; Efficacy and safety of 4 months of sublingual immunotherapy with recombinant Mal d 1 and Bet v 1 in patients with birch pollen-related apple allergy. J Allergy Clin Immunol 2018,141(3),1002-1008 · DOI
  68. Siebeneicher S.; Reuter S.; Krause M.; Wangorsch A.; Maxeiner J.; Wolfheimer S.; Schülke S.; Naito S.; Heinz A.; Taube C.; Vieths S.; Scheurer S.; Toda M.; Epicutaneous immune modulation with Bet v 1 plus R848 suppresses allergic asthma in a murine model. Allergy 2014,69(3),328-337 · DOI
  69. Hufnagl K.; Afify S.M.; Braun N.; Wagner S.; Wallner M.; Hauser M.; Wiederstein M.; Gadermaier G.; Wildner S.; Redegeld F.A.; Blokhuis B.R.; Hofstetter G.; Pali-Schöll I.; Roth-Walter F.; Pacios L.F.; Jensen-Jarolim E.; Retinoic acid-loading of the major birch pollen allergen Bet v 1 may improve specific allergen immunotherapy: In silico, in vitro and in vivo data in BALB/c mice. Allergy 2020,75(8),2073-2077 · DOI
  70. Machado Y.; Duinkerken S.; Hoepflinger V.; Mayr M.; Korotchenko E.; Kurtaj A.; Pablos I.; Steiner M.; Stoecklinger A.; Lübbers J.; Schmid M.; Ritter U.; Scheiblhofer S.; Ablinger M.; Wally V.; Hochmann S.; Raninger A.M.; Strunk D.; van Kooyk Y.; Thalhamer J.; Weiss R.; Synergistic effects of dendritic cell targeting and laser-microporation on enhancing epicutaneous skin vaccination efficacy. J Control Release 2017,266,87-99 · DOI
  71. Linhart B.; Narayanan M.; Focke-Tejkl M.; Wrba F.; Vrtala S.; Valenta R.; Prophylactic and therapeutic vaccination with carrier-bound Bet v 1 peptides lacking allergen-specific T cell epitopes reduces Bet v 1-specific T cell responses via blocking antibodies in a murine model for birch pollen allergy. Clin Exp Allergy 2014,44(2),278-287 · DOI
  72. Flicker S.; Linhart B.; Wild C.; Wiedermann U.; Valenta R.; Passive immunization with allergen-specific IgG antibodies for treatment and prevention of allergy. Immunobiology 2013,218(6),884-891 · DOI
  73. Weinberger E.E.; Isakovic A.; Scheiblhofer S.; Ramsauer C.; Reiter K.; Hauser-Kronberger C.; Thalhamer J.; Weiss R.; The influence of antigen targeting to sub-cellular compartments on the anti-allergic potential of a DNA vaccine. Vaccine 2013,31(51),6113-6121 · DOI
  74. Kitzmüller C.; Kalser J.; Mutschlechner S.; Hauser M.; Zlabinger G.J.; Ferreira F.; Bohle B.; Fusion proteins of flagellin and the major birch pollen allergen Bet v 1 show enhanced immunogenicity, reduced allergenicity, and intrinsic adjuvanticity. J Allergy Clin Immunol 2018,141(1),293-299.e6 · DOI
  75. Marth K.; Breyer I.; Focke-Tejkl M.; Blatt K.; Shamji M.H.; Layhadi J.; Gieras A.; Swoboda I.; Zafred D.; Keller W.; Valent P.; Durham S.R.; Valenta R.; A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS-fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol 2013,190(7),3068-3078 · DOI
  76. Hofer H.; Asam C.; Hauser M.; Nagl B.; Laimer J.; Himly M.; Briza P.; Ebner C.; Lang R.; Hawranek T.; Bohle B.; Lackner P.; Ferreira F.; Wallner M.; Tackling Bet v 1 and associated food allergies with a single hybrid protein. J Allergy Clin Immunol 2017,140(2),525-533.e10 · DOI
  77. Najafi N.; Hofer G.; Gattinger P.; Smiljkovic D.; Blatt K.; Selb R.; Stoecklinger A.; Keller W.; Valent P.; Niederberger V.; Thalhamer J.; Valenta R.; Flicker S.; Fusion proteins consisting of Bet v 1 and Phl p 5 form IgE-reactive aggregates with reduced allergenic activity. Sci Rep 2019,9(1),4006 · DOI
  78. Siebeneicher S.; Reuter S.; Wangorsch A.; Krause M.; Foetisch K.; Heinz A.; Naito S.; Reuter A.; Taube C.; Vieths S.; Scheurer S.; Toda M.; Epicutaneous immunotherapy with a hypoallergenic Bet v 1 suppresses allergic asthma in a murine model. Allergy 2015,70(12),1559-1568 · DOI
  79. Kitzmüller C.; Wallner M.; Deifl S.; Mutschlechner S.; Walterskirchen C.; Zlabinger G.J.; Ferreira F.; Bohle B.; A hypoallergenic variant of the major birch pollen allergen shows distinct characteristics in antigen processing and T-cell activation. Allergy 2012,67(11),1375-1382 · DOI
  80. Pichler U.; Asam C.; Weiss R.; Isakovic A.; Hauser M.; Briza P.; Ferreira F.; Wallner M.; The fold variant BM4 is beneficial in a therapeutic Bet v 1 mouse model. BioMed Res Int 2013,2013,832404 · DOI
  81. Aglas L.; Bethanis A.; Chrusciel P.; Stolz F.; Gruen M.; Jaakkola U.M.; Jongejan L.; Yatkin E.; Van Ree R.; In vivo Induction of Functional Inhibitory IgG Antibodies by a Hypoallergenic Bet v 1 Variant. Front Immunol 2020,11,2118 · DOI
  82. Pellaton C.; Perrin Y.; Boudousquié C.; Barbier N.; Wassenberg J.; Corradin G.; Thierry A.C.; Audran R.; Reymond C.; Spertini F.; Novel birch pollen specific immunotherapy formulation based on contiguous overlapping peptides. Clin Transl Allergy 2013,3(1),17 · DOI
  83. Airouche S.; Beltrami V.; Fleury S.; Batard T.; Bordas-Le Floch V.; Stegmann T.; Amacker M.; Kettner A.; Mascarell L.; Bet v 1 contiguous overlapping peptides anchored to virosomes with TLR4 agonist enhance immunotherapy efficacy in mice. Clin Exp Allergy 2021,51(2),339-349 · DOI
  84. Petrarca C.; Clemente E.; Toto V.; Iezzi M.; Rossi C.; Zanotta S.; Mistrello G.; Zanoni I.; Granucci F.; Arioli S.; Mora D.; Guglielmetti S.; Paganelli R.; Di Gioacchino M.; rBet v 1 immunotherapy of sensitized mice with Streptococcus thermophilus as vehicle and adjuvant. Hum Vaccin Immunother 2014,10(5),1228-1237 · DOI
  85. Tourdot S.; Airouche S.; Berjont N.; Moussu H.; Betbeder D.; Nony E.; Bordas-Le Floch V.; Baron-Bodo V.; Mascarell L.; Moingeon P.; Efficacy of sublingual vectorized recombinant Bet v 1a in a mouse model of birch pollen allergic asthma. Vaccine 2013,31(23),2628-2637 · DOI
  86. Cabauatan C.R.; Campana R.; Niespodziana K.; Reinisch C.; Lundberg U.; Meinke A.; Henning R.; Neubauer A.; Valenta R.; Heat-labile Escherichia coli toxin enhances the induction of allergen-specific IgG antibodies in epicutaneous patch vaccination. Allergy 2017,72(1),164-168 · DOI
  87. Trivedi B.; Valerio C.; Slater J.E.; Endotoxin content of standardized allergen vaccines. J Allergy Clin Immunol 2003,111(4),777-783 · DOI
  88. van Ree R.; Chapman M.D.; Ferreira F.; Vieths S.; Bryan D.; Cromwell O.; Villalba M.; Durham S.R.; Becker W.M.; Aalbers M.; André C.; Barber D.; Cistero Bahima A.; Custovic A.; Didierlaurent A.; Dolman C.; Dorpema J.W.; Di Felice G.; Eberhardt F.; Fernandez Caldas E.; Fernandez Rivas M.; Fiebig H.; Focke M.; Fötisch K.; Gadermaier G.; Das R.G.; Gonzalez Mancebo E.; Himly M.; Kinaciyan T.; Knulst A.C.; Kroon A.M.; Lepp U.; Marco F.M.; Mari A.; Moingeon P.; Monsalve R.; Neubauer A.; Notten S.; Ooievaar-de Heer P.; Pauli G.; Pini C.; Purohit A.; Quiralte J.; Rak S.; Raulf-Heimsoth M.; San Miguel Moncin M.M.; Simpson B.; Tsay A.; Vailes L.; Wallner M.; Weber B.; The CREATE project: Development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008,63(3),310-326 · DOI
  89. Himly M.; Nony E.; Chabre H.; Van Overtvelt L.; Neubauer A.; van Ree R.; Buchheit K.H.; Vieths S.; Moingeon P.; Ferreira F.; Standardization of allergen products: 1. Detailed characterization of GMP-produced recombinant Bet v 1.0101 as biological reference preparation. Allergy 2009,64(7),1038-1045 · DOI
  90. Zimmer J.; Vieths S.; Kaul S.; Standardization and Regulation of Allergen Products in the European Union. Curr Allergy Asthma Rep 2016,16(3),21 · DOI
  91. Pauli G.; Larsen T.H.; Rak S.; Horak F.; Pastorello E.; Valenta R.; Purohit A.; Arvidsson M.; Kavina A.; Schroeder J.W.; Mothes N.; Spitzauer S.; Montagut A.; Galvain S.; Melac M.; André C.; Poulsen L.K.; Malling H.J.; Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol 2008,122(5),951-960 · DOI
  92. Köhler V.K.; Crescioli S.; Fazekas-Singer J.; Bax H.J.; Hofer G.; Pranger C.L.; Hufnagl K.; Bianchini R.; Flicker S.; Keller W.; Karagiannis S.N.; Jensen-Jarolim E.; Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG1 and IgG4 against the Major Birch Pollen Allergen Bet v 1. Int J Mol Sci 2020,21(16),5693 · DOI
  93. Atanasio A.; Franklin M.C.; Kamat V.; Hernandez A.R.; Badithe A.; Ben L.H.; Jones J.; Bautista J.; Yancopoulos G.D.; Olson W.; Murphy A.J.; Sleeman M.A.; Orengo J.M.; Targeting immunodominant Bet v 1 epitopes with monoclonal antibodies prevents the birch allergic response. J Allergy Clin Immunol Epub ahead of print.2021
  94. Ballmer-Weber B.K.; Wüthrich B.; Wangorsch A.; Fötisch K.; Altmann F.; Vieths S.; Carrot allergy: Double-blinded, placebo-controlled food challenge and identification of allergens. J Allergy Clin Immunol 2001,108(2),301-307 · DOI
  95. Pastorello E.A.; Pravettoni V.; Ispano M.; Farioli L.; Ansaloni R.; Rotondo F.; Incorvaia C.; Asman I.; Bengtsson A.; Ortolani C.; Identification of the allergenic components of kiwi fruit and evaluation of their cross-reactivity with timothy and birch pollens. J Allergy Clin Immunol 1996,98(3),601-610 · DOI
  96. Ebner C.; Hirschwehr R.; Bauer L.; Breiteneder H.; Valenta R.; Ebner H.; Kraft D.; Scheiner O.; Identification of allergens in fruits and vegetables: IgE cross-reactivities with the important birch pollen allergens Bet v 1 and Bet v 2 (birch profilin). J Allergy Clin Immunol 1995,95(5 Pt 1),962-969 · DOI
  97. Skypala I.J.; Bull S.; Deegan K.; Gruffydd-Jones K.; Holmes S.; Small I.; Emery P.W.; Durham S.R.; The prevalence of PFS and prevalence and characteristics of reported food allergy; a survey of UK adults aged 18-75 incorporating a validated PFS diagnostic questionnaire. Clin Exp Allergy 2013,43(8),928-940 · DOI
  98. Carlson G.; Coop C.; Pollen food allergy syndrome (PFAS): A review of current available literature. Ann Allergy Asthma Immunol 2019,123(4),359-365 · DOI · Paper page
  99. Olcese R.; Silvestri M.; Del Barba P.; Brolatti N.; Barberi S.; Tosca M.A.; Ciprandi G.; Mal d 1 and Bet v 1 sensitization pattern in children with Pollen Food Syndrome. Allergol Int 2019,68(1),122-124 · DOI
  100. Asero R.; Massironi F.; Velati C.; Detection of prognostic factors for oral allergy syndrome in patients with birch pollen hypersensitivity. J Allergy Clin Immunol 1996,97(2),611-616 · DOI
  101. Park K.H.; Son Y.W.; Lee S.C.; Jeong K.; Sim W.; Park H.J.; Lee S.; Lee J.H.; Park J.W.; Clinical Significance of Component Allergens in Fagales Pollen-Sensitized Peanut Allergy in Korea. Allergy Asthma Immunol Res 2016,8(6),505-511 · DOI
  102. Asero R.; Relevance of pollen-specific IgE levels to the development of Apiaceae hypersensitivity in patients with birch pollen allergy. Allergy 1997,52(5),560-564 · DOI
  103. Fernández-Rivas M.; van Ree R.; Cuevas M.; Allergy to Rosaceae fruits without related pollinosis. J Allergy Clin Immunol 1997,100(6 Pt 1),728-733 · DOI
  104. Fernández-Rivas M.; Bolhaar S.; González-Mancebo E.; Asero R.; van Leeuwen A.; Bohle B.; Ma Y.; Ebner C.; Rigby N.; Sancho A.I.; Miles S.; Zuidmeer L.; Knulst A.; Breiteneder H.; Mills C.; Hoffmann-Sommergruber K.; van Ree R.; Apple allergy across Europe: How allergen sensitization profiles determine the clinical expression of allergies to plant foods. J Allergy Clin Immunol 2006,118(2),481-488 · DOI

Cited by

Sorted by citations

Metadata

Authors
Guan, K., Li, L., & Chang, C.
Affiliations
  • Department of Allergy, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing Key Laboratory of Precision Medicine for Diagnosis and Treatment on Allergic Diseases, National Clinical Research Center for Dermatologic and Immunologic Diseases, Beijing, China, 100730
  • Division of Rheumatology, Allergy and Clinical Immunology, University of California, Davis, Davis, CA 95616, USA
Venue
Current Protein & Peptide Science
Publisher
Bentham Science Publishers Ltd.
Published
2022-11
Volume
23
Issue
11
Pages
731-743
ISSN
1389-2037
DOI
10.2174/1389203723666220815095725
Cited by
19
References
2
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review